- Global Pharma News & Resources

£6 million investment to benefit the treatment of cancer patients worldwide

£6 million investment to benefit the treatment of cancer patients worldwide

Mirada Medical injects funds into new AI-based imaging software to lead the transformation of radiation oncology

Oxford, 8 April 2019 -  Mirada Medical, a world leading medical imaging software company, has announced a new £6 million investment to support the development of artificial intelligence (AI) based software which will increase the speed and accuracy of cancer treatment planning applications, while delivering a more personalised level of care to patients.

Mirada’s state of the art software algorithms and imaging applications help clinicians to simplify technically complex image processing tasks, thus helping them use medical images more effectively and improve cancer care.

Mark Gooding, CTO at Mirada Medical, said “Incidence of cancer is expected to increase globally by 62% by 2040. There were approximately 17 million new cancer patients worldwide in 2018 and we estimate half of them will receive radiation oncology as part of their treatment, thus potentially benefitting from this technology. We believe that AI can be rapidly applied to every-day laborious healthcare tasks such as contouring, enabling clinical staff to spend more of their valuable time working directly with their patients to deliver optimal healthcare outcomes.”

Through its global leadership in medical software technology and deep learning AI, Mirada recently scored an industry first by gaining FDA clearance for its Deep Learning Contouring treatment planning solution, DLCExpert™. The product automates time-consuming critical structure contouring tasks, which are an essential part of the treatment planning process.

The software has been clinically validated and is in daily clinical use at a number of leading hospitals and health centres around the world, including The University Medical Centre, Groningen in the Netherlands and the Institut Curie in France. The investment, led by private equity healthcare specialists, Apposite Capital, alongside Mirada’s founding investor, AlbionVC, and other private investors will enable Mirada to accelerate product development milestones, and improve the market accessibility of its AI-based software applications, helping clinicians to improve healthcare outcomes for patients worldwide.

Hugh Bettesworth, Mirada’s CEO, said “The use of AI in healthcare is growing quickly. We are excited to be able to accelerate our development of AI based cancer treatment planning. This new investment provides Mirada with invaluable resource so that our products will make a transformative impact on the day-to-day provision of cancer care, through the deployment of advanced AI-powered technology.”

– ends –

 Mirada Medical, RTx and Workflow Box are trademarks of Mirada Medical Ltd.

About Mirada Medical

Mirada Medical is a leading international brand in medical imaging. The company develops advanced technology applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

The company specialises in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention. Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.

For more information, please contact:

Annamaria Albano                                                                                  Lucia Giffard

Mirada Medical Ltd                                                                                                Four Health Communications

Oxford Centre for Innovation                                                                  Tel: +44(0)2037614493

New Road, Oxford                                                                        

OX1 1BY United Kingdom

Tel: +44(0)1865 261


Editor Details

Last Updated: 09-Apr-2019